advertisement
Abstract #8985 Published in IGR 5-2
Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension
Noecker RJ; Earl ML; Mundorf T; Peace J; Williams RDAdvances in Therapy 2003; 20: 121-128
This randomized, investigator-masked, multicenter, parallel-design trial compared the intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in African Americans with glaucoma or ocular hypertension. After washout of all ocular hypotensive agents, patients were assigned to bimatoprost once daily (n=16) or travoprost once daily (n=15) for three months. Study visits were at baseline and at months 1, 2, and 3. Primary outcome measures were the percentage of patients who achieved selected target pressures and the mean reduction in IOP from baseline at month 3. Both drugs comparably lowered IOP, but bimatoprost was more likely than travoprost to allow achievement of every target pressure from 12-19 mmHg at month 3. After three months, mean IOP reduction from baseline was 8.4 mmHg (34%) in the bimatoprost group and 7.9 mmHg (30%) in the travoprost group. These results are being evaluated further in a larger clinical trial.
Dr. R.J. Noecker, Department of Ophthalmology, University of Arizona, Tucson, AZ 85711, USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)